A pharmacometrician’s role in enhancing medication use in pregnancy and lactation by Quinney, Sara K. & Bonate, Peter L.
COMMENTARY
A pharmacometrician’s role in enhancing medication use in pregnancy
and lactation
Sara K. Quinney1 • Peter L. Bonate2
Published online: 16 August 2020
 The Author(s) 2020
Over 200 million pregnancies occur worldwide annually
[1], yet pregnant women have historically been excluded
from clinical studies. However, women who are pregnant
are not immune to chronic disease (e.g. asthma, seizure
disorders) or acute illnesses (e.g. viral infections or inju-
ries). Additionally, pregnant women suffer from conditions
associated with the pregnancy such as gestational diabetes
or hypertension. Many women therefore need medication
treatment during their pregnancy. Over 68% of women
report taking at least one prescription drug, excluding
vitamins, during their pregnancy, with a large proportion of
women taking for or more drugs [2].
Prior to the early 1990s, women were largely under-
represented in clinical research, and pregnant women were
summarily excluded from participation in clinical trials [3].
In fact, if a woman enrolled in a drug trial became pregnant
during the course of the study, she was often removed from
the study drug immediately. However, physiology differs
between women and men, and between nonpregnant and
pregnant women, leading to differences in drug distribution
and response. It is difficult to extrapolate the effects of a
drug that are observed in men to pregnant women. The
National Institutes of Health Revitalization Act of 1993
required that women be included in NIH-funded studies
unless it is inappropriate to the health of the subject or
purpose of the research [4]. The Institute of Medicine’s
committee on Women and Health Research unanimously
asserted that ‘‘pregnant women be presumed to be eligible
for participation in clinical studies.’’ [3] The committee
also debated whether pregnant women should only be
excluded from participation in research when there is no
likelihood of medical benefit in pregnant women or when
risk of harm to the fetus is known or can be inferred from
preclinical studies. In spite of this, many Institutional
Review Boards (IRB’s) continue to view pregnancy as an
automatic reason to exclude women from clinical trials.
This practice has left pregnant women as clinical orphans.
Pharmacometrics, including pharmacokinetic/pharma-
codynamic modeling, systems pharmacology, and machine
learning approaches, provides a valuable tool set for opti-
mizing drug therapy in pregnant women. This themed issue
of The Journal of Pharmacokinetics and Pharmacody-
namics focuses on the challenges of conducting drug
studies in pregnant and lactating women and the opportu-
nities for pharmacometricians and data scientists to
enhance research in this area. McKiever et al. provide a
historical background of inclusion of pregnant women in
clinical studies from initial experiences with diethyl-
stilbestrol (DES) and thalidomide, which led to legislative
changes excluding women of reproductive age from early
phase clinical trials, to current philosophy recognizing the
importance of well-conducted clinical studies in this pop-
ulation [5]. They also provide an example of repurposing
pravastatin, a previously Category X medication, for pre-
vention of preeclampsia. This case also demonstrates the
significance of the FDA’s pregnancy labeling change
which replaced the categorical labeling system with more
detailed information on studies in pregnancy.
Physiologically based pharmacokinetic (PBPK) model-
ing is a valuable tool for assessing changes in pharma-
cokinetics during pregnancy. PBPK models provide a
means of incorporating physiological changes across
pregnancy with knowledge of a drug’s ADMET charac-
teristics to predict changes in PK across gestation. In this
issue, Kazma et al. review anatomical and physiological
changes in pregnant women and how they can be used to
inform PBPK models [6]. Abduljalil et al. provide
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examples of how PBPK modeling can inform drug dosing
in pregnancy and estimate fetal drug exposure [7]. They
also provide examples of individualizing dosing based
upon additional covariates, such as pharmacogenomics or
drug-drug interactions.
The maternal-infant connection does not end at delivery.
95% of women worldwide breastfeed their infants at least
once, and 40–60% of infants are breastfed for the first 2
years of life [8]. The American Academy of Pediatrics
recommends exclusive breastfeeding for the first 6 months
of life [9]. With no regulatory requirement to conduct drug
studies in lactating women, there is a paucity of data on
pharmacokinetics and safety of drugs in this population.
The complexity of maternal and infant physiological
changes postpartum, including variability in milk produc-
tion and infant feeding patterns complicate pharmacoki-
netic studies in breastfeeding. In this issue, Anderson and
Momper describe current best practices in pharmacokinetic
studies in lactating women and estimation of infant dose
[10]. They also describe challenges in conducting clinical
lactation studies and limitations to the use of pharma-
cokinetic modeling approaches, including integration with
in utero exposure and limited knowledge of postpartum
physiological changes.
The burgeoning field of artificial intelligence (AI),
including machine learning, has shown promise in opti-
mizing drug use in a number of areas including oncology,
diabetes and anesthesia [11–13]. Yet, few studies have
applied AI to pharmacological studies in pregnancy and
lactation. Davidson and Boland conducted a systematic
review of literature relating to AI in pregnancy [14]. They
identified studies relating to obtaining data from clinical
records, clinical decision support focusing on diagnosis and
disease management, and prediction of birth outcomes
were identified. However, relatively few papers incorpo-
rated pharmacological data. Harnessing the potential of AI
to enhance pharmacological therapy in pregnancy and
lactation has great promise to inform medication safety and
efficacy for both mother and child.
Great progress has been made in the field of obstetric
clinical pharmacology over the past decade, thanks in part
to new FDA Guidances [15, 16] and NIH funding initia-
tives, including the Obstetric Pharmacology Research
Centers [17]. While there has been some growth in
obstetric pharmacology over the past decade, the number of
studies published regarding pharmacokinetics in pregnancy
and lactation remains abysmal. A search of Pubmed for
‘‘pharmacokinetics’’ and ‘‘pregnancy’’ clinical trials returns
less than 40 publications a year; the number of lactation
studies is in the single digits. Clinicaltrials.gov lists only 77
active or planned studies including the terms ‘‘pregnancy’’
and ‘‘pharmacokinetics’’, with less than half of those
receiving support from pharmaceutical industry. Yet, every
individual alive today has been affected by pregnancy.
With the large majority of pregnant women taking medi-
cation, it is critical that we understand how pregnancy
alters the pharmacokinetics of drugs both for optimized
treatment of maternal conditions and safety of the devel-
oping fetus. The advantages of breastfeeding are numerous
[9], yet women will often discontinue breastfeeding due to
fear of how a drug may affect their child [18]. Often these
concerns are unfounded. However, with the paucity of
studies providing information on drug exposure to breast-
fed infants women err on the side of ‘‘safety’’, while
inadvertently withholding a valuable resource from their
infant.
As discussed in a recent New England Journal of
Medicine perspective, more work is needed to ‘‘get it
right’’ [19]. What is missing from the New England Journal
perspective is the role of quantitative pharmacology
approaches to augment study design and analysis of the
often sparse data available from clinical obstetric studies.
Pharmacometrics, systems pharmacology, artificial intelli-
gence, and other novel quantitative approaches provide
important tools to explore the pharmacokinetics and phar-
macodynamics of drugs in pregnancy and lactation while
minimizing risk to mother and baby.
Including pharmacokinetic sampling in studies of
pregnant and lactating women should become the rule, not
the exception. It is critical for clinical pharmacologists and
pharmacometricians to be consulted early in protocol
development. Within the department of one of this edito-
rial’s authors (Quinney), she has been asked to evaluate
drug concentrations in samples that have been previously
collected. Often, she finds that the study design is inade-
quate or that the addition of one or two well-timed sample
collections would have greatly magnified the knowledge
gained. Linking risk to medication use during pregnancy
also requires a more granular level of data than is typically
collected in studies. Large prospective cohort studies of
pregnant and lactating women should strive to collect well-
characterized medication use data during pregnancy and
lactation, including information on timing and dosing.
Asking ‘‘what medications have you taken?’’ will not
provide information on how much medication was taken
and when. Investigators should leverage use of electronic
health records, wearables, and other information resources
through integrative pharmacometric and machine learning
approaches to enhance understanding of pharmacotherapy
in pregnancy and lactation. While there has been an
upsurge in PBPK modeling in obstetrics, additional studies
are required to validate the assumptions of these models
and further understand sources of inter- and intra-individ-
ual variability.
Finally, in order to benefit patients, results of studies
must be implemented into widespread clinical practice. A
123
268 Journal of Pharmacokinetics and Pharmacodynamics (2020) 47:267–269
survey of American Academy of Allergy, Asthma &
Immunology membership found that less than half of
clinicians were not aware of the FDA’s pregnancy and
lactation labeling changes and 95% continued to use the
pregnancy letter categories [20]. This indicates the diffi-
culty in disseminating new knowledge to stakeholders.
Pharmacometricians should work in tandem with the
informatics and medical communities to develop clinical
decision support systems to move knowledge gained from
obstetric and lactation pharmacology research to clinicians
and patients.
Research in obstetric pharmacology has advanced
greatly over the past decades. However, much work
remains to be done. By exploiting tools commonly applied
to other diseases, pharmacometricians can play a signifi-
cant role in optimizing drug therapy in pregnant and lac-
tating women. Not only is the health of women at stake, but
also the health of future generations.
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